Assembly Biosciences (NASDAQ:ASMB) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “

A number of other equities analysts also recently weighed in on the stock. Chardan Capital reissued a hold rating on shares of Assembly Biosciences in a report on Sunday, June 30th. BidaskClub downgraded shares of Walgreens Boots Alliance from a sell rating to a strong sell rating in a report on Monday, June 24th. Finally, William Blair reissued an outperform rating on shares of Assembly Biosciences in a report on Friday, May 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of Hold and an average price target of $41.20.

Shares of NASDAQ:ASMB opened at $13.38 on Wednesday. The business has a 50-day moving average of $14.35. The company has a quick ratio of 7.97, a current ratio of 7.97 and a debt-to-equity ratio of 0.06. The stock has a market cap of $341.86 million, a P/E ratio of -3.36 and a beta of 1.46. Assembly Biosciences has a fifty-two week low of $12.75 and a fifty-two week high of $44.65.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.06) by $0.01. The company had revenue of $3.89 million for the quarter, compared to the consensus estimate of $3.81 million. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. As a group, analysts predict that Assembly Biosciences will post -4.34 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc raised its stake in Assembly Biosciences by 17.0% in the 4th quarter. Legal & General Group Plc now owns 3,847 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 558 shares during the period. United Services Automobile Association raised its stake in Assembly Biosciences by 1.1% in the 4th quarter. United Services Automobile Association now owns 51,764 shares of the biopharmaceutical company’s stock valued at $1,171,000 after acquiring an additional 560 shares during the period. Valeo Financial Advisors LLC raised its stake in Assembly Biosciences by 0.5% in the 1st quarter. Valeo Financial Advisors LLC now owns 201,000 shares of the biopharmaceutical company’s stock valued at $3,958,000 after acquiring an additional 1,000 shares during the period. JGP Global Gestao de Recursos Ltda. raised its stake in Assembly Biosciences by 10.4% in the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 15,344 shares of the biopharmaceutical company’s stock valued at $302,000 after acquiring an additional 1,447 shares during the period. Finally, FMR LLC raised its stake in Assembly Biosciences by 0.6% in the 1st quarter. FMR LLC now owns 445,716 shares of the biopharmaceutical company’s stock valued at $8,776,000 after acquiring an additional 2,680 shares during the period. Institutional investors and hedge funds own 86.44% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Read More: How Investors Use a Balance Sheet

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.